Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
1-[(2R)-2-Aminobutanoyl]-N-(3-chlorobenzyl)-L-prolinamide is a synthetic small molecule dipeptide, characterized by a prolinamide backbone with an aminobutanoyl group and a 3-chlorobenzyl substituent. It has the molecular formula C16H22ClN3O2 and a molecular weight of approximately 323.82 g/mol[1][5][10]. The compound is listed as experimental and does not have any approved medical indications or known clinical development beyond preclinical or early research phases[2]. Its mechanism of action, biological targets, pharmacological activity, and therapeutic potential are not described in publicly available sources. There are no records of its use in clinical trials for any disease indication.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 1-[(2R)-2-aminobutanoyl]-N-(3-chlorobenzyl)-L-prolinamide.